GlassScriptPhysician profile
Jamie Geier
NPI 1417358672
$8,381.06
in general payments reported to CMS, 2019-2025
52 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,564 · 2022: $1,456 · 2023: $1,224 · 2024: $2,049 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,127.68 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $807.53 | 2021-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $802.01 | 2021-2025 | |
| Lilly USA, LLC | $719.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $450.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $431.90 | 2021-2025 | |
| Astellas Pharma US INC | $396.65 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.82 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $350.80 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $257.55 | 2021-2023 | Belsomra, Steglujan, Steglatro |
| Vanda Pharmaceuticals INC. | $227.66 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $183.38 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $174.78 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $173.20 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $158.41 | 2021-2025 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Geier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.